Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Michele Pachanski"'
Autor:
Barbara Pio, Ravi P. Nargund, Yan Guo, Daniel Kosinski, Josien Hubert B, Michael Wright, Michele Pachanski, Harry R. Chobanian, Xiaoping Zhang, Richard Tschirret-Guth, Melissa Kirkland, Andrew D. Howard, Sarah Souza, Eric R. Ashley, Robert K. Orr, Steven L. Colletti, Joel Mane, Jerry Di Salvo, Michael W. Miller, Boonlert Cheewatrakoolpong, Koppara Samuel, William K. Hagmann, James Lamca, Juliann Ehrhart, Maria E. Trujillo, Jackie Shang, Qing Chen, Adam B. Weinglass, Randal M. Bugianesi
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 29:1842-1848
GPR40 (FFAR1 or FFA1) is a G protein-coupled receptor, primarily expressed in pancreatic islet β-cells and intestinal enteroendocrine cells. When activated by fatty acids, GPR40 elicits increased insulin secretion from islet β-cells only in the pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67130fd906c302e54806df711af08d1b
https://doi.org/10.1016/j.bmcl.2019.04.050
https://doi.org/10.1016/j.bmcl.2019.04.050
Autor:
Judith N. Gorski, Maria E. Trujillo, Brande Thomas-Fowlkes, Adam B. Weinglass, Jerry Di Salvo, Aimie M. Ogawa, Sarah Souza, Christopher W. Plummer, Joel Mane, Michele Pachanski, Boonlert Cheewatrakoolpong, Andrew D. Howard, Steven L. Colletti
Publikováno v:
American Journal of Physiology-Endocrinology and Metabolism. 313:E37-E47
G protein-coupled receptor 40 (GPR40) partial agonists lower glucose through the potentiation of glucose-stimulated insulin secretion, which is believed to provide significant glucose lowering without the weight gain or hypoglycemic risk associated w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cc4daac847ef7e96602196782cbdb63
https://doi.org/10.1152/ajpendo.00435.2016
https://doi.org/10.1152/ajpendo.00435.2016
Autor:
Bei Zhang, Jiayi Xu, Robert W. Myers, Roman Kats-Kagan, Qinghong Fu, Sunita Malkani, Hsuan-shen Chen, Rui Zhang, Maria E. Trujillo, Michael Kavana, Daniel R. McMasters, Brian T. Campbell, George H. Addona, George J. Eiermann, Zhesheng Chen, Michele Pachanski, Fengqi Zhang, Brian T. Farrer, Kaushik Mitra, Libo Xu, Nadine Elowe, Joel P. Berger, Emma R. Parmee, Songnian Lin, Wen Feng, Xinchun Tong
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 27:2069-2073
Glucokinase (GK, hexokinase IV) is a unique hexokinase that plays a central role in mammalian glucose homeostasis. Glucose phosphorylation by GK in the pancreatic β-cell is the rate-limiting step that controls glucose-stimulated insulin secretion. S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f297c94aef86ac210547893541fab565
https://doi.org/10.1016/j.bmcl.2016.10.085
https://doi.org/10.1016/j.bmcl.2016.10.085
Autor:
Melissa Kirkland, Randal M. Bugianesi, Melodie Christensen, Maria E. Trujillo, Michele Pachanski, Richard Tschirret-Guth, Josien Hubert B, Adam B. Weinglass, Sarah Souza, Ravi P. Nargund, Christopher W. Plummer, Andrew D. Howard, Joel Mane, Louis-Charles Campeau, Robert K. Orr, Daniel Kosinski, Xiaoping Zhang, Boonlert Cheewatrakoolpong, Jerry Di Salvo, Michael W. Miller, William K. Hagmann, Helen Chen, Steven L. Colletti, Andrew Nolting, Michael Wright, Matthew J. Clements, Murali Rajagopalan
Publikováno v:
ACS Medicinal Chemistry Letters. 8:221-226
GPR40 is a G-protein-coupled receptor expressed primarily in pancreatic islets and intestinal L-cells that has been a target of significant recent therapeutic interest for type II diabetes. Activation of GPR40 by partial agonists elicits insulin secr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6942c1dd589ae2364bd7ea069018de04
https://doi.org/10.1021/acsmedchemlett.6b00443
https://doi.org/10.1021/acsmedchemlett.6b00443
Autor:
Melissa Kirkland, M A Powles, Francisco Velazquez, Eric R. Ashley, Nengxue Wang, Shah Unmesh G, Feroze Ujjainwalla, Taro E. Akiyama, Eric J. Gilbert, Charles Lee Jayne, Michele Pachanski, Dan Zhou, Scott D. Edmondson, Jerry Di Salvo, Andreas Verras, Maria Madeira, Takao Suzuki, Srikanth Venkatraman, Quang Truong, Wu Yin, Gregory L. Adams, Shouwu Miao
Publikováno v:
ACS Medicinal Chemistry Letters. 8:96-101
GPR120 (FFAR4) is a fatty acid sensing G protein coupled receptor (GPCR) that has been identified as a target for possible treatment of type 2 diabetes. A selective activator of GPR120 containing a chromane scaffold has been designed, synthesized, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5c4bd187bc901f79299111d7c132c57
https://doi.org/10.1021/acsmedchemlett.6b00394
https://doi.org/10.1021/acsmedchemlett.6b00394
Autor:
Matthew Lombardo, Eric N. Johnson, John Cummings, Jerry Di Salvo, Thomas Roussel, James R. Tata, Melissa Kirkland, Michael A. Plotkin, Christopher Joseph Sinz, Feroze Ujjainwalla, Dennis Leung, Dorina Trusca, Joel Mane, Taro E. Akiyama, Alejandro Crespo, Mary Ann Powles, Kate Bender, Michael F.A. Finley, Joanna Pols, Candice Alleyne, Michele Pachanski, Andrew D. Howard, Wayne M. Geissler, Ying Lei, Bahanu Habulihaz, Victor N. Uebele, Clare London, Maria Madeira
Publikováno v:
Bioorganicmedicinal chemistry letters. 27(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a15bdf4d7ae8e579647d40689c42f33e
https://pubmed.ncbi.nlm.nih.gov/27815121
https://pubmed.ncbi.nlm.nih.gov/27815121
Autor:
Daniel Kosinski, Melissa Kirkland, Michelle Bunzel, Jin Cao, Robert W. Myers, Adam B. Weinglass, Kevin Knagge, Michele Pachanski, Sarah Souza, William K. Hagmann, Joel Mane, Xiaoyan Li, Maria E. Trujillo, Corin O. Miller, Paul E. Carrington, Jerry Di Salvo, Brande Thomas-Fowlkes
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0176182 (2017)
PLoS ONE
PLoS ONE
GPR40 (FFA1) is a fatty acid receptor whose activation results in potent glucose lowering and insulinotropic effects in vivo. Several reports illustrate that GPR40 agonists exert glucose lowering in diabetic humans. To assess the mechanisms by which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26bfccec2b21e6b21432c0056bc58040
http://europepmc.org/articles/PMC5441580?pdf=render
http://europepmc.org/articles/PMC5441580?pdf=render
Autor:
John S. Debenham, Dann L. Parker, Birgit T. Priest, Ravi P. Nargund, Feroze Ujjainwalla, Randal M. Bugianesi, Michele Pachanski, Liangqin Guo, William K. Hagmann, George J. Eiermann, Yi Zang, Ramzi F. Sweis, Andrew D. Howard, Jenna L. Terebetski, Melissa Kirkland, Yue Feng, Gino Salituro, Derun Li, Christopher Joseph Sinz, Stan Mitelman, Maria E. Trujillo, Scott D. Edmondson, Karen H. Dingley, Jin Shang, Nicole Buist, Xiaofang Li, Weiguo Liu, Mary Ann Powles, Terri M. Kelly, Edward C. Sherer
GPR142 has been identified as a potential glucose-stimulated insulin secretion (GSIS) target for the treatment of type 2 diabetes mellitus (T2DM). A class of triazole GPR142 agonists was discovered through a high throughput screen. The lead compound
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05666abdc0e69d7961b4edf099a12f0b
https://europepmc.org/articles/PMC5150677/
https://europepmc.org/articles/PMC5150677/
Autor:
Gregory L, Adams, Francisco, Velazquez, Charles, Jayne, Unmesh, Shah, Shouwu, Miao, Eric R, Ashley, Maria, Madeira, Taro E, Akiyama, Jerry, Di Salvo, Takao, Suzuki, Nengxue, Wang, Quang, Truong, Eric, Gilbert, Dan, Zhou, Andreas, Verras, Melissa, Kirkland, Michele, Pachanski, Maryann, Powles, Wu, Yin, Feroze, Ujjainwalla, Srikanth, Venkatraman, Scott D, Edmondson
Publikováno v:
ACS medicinal chemistry letters. 8(1)
GPR120 (FFAR4) is a fatty acid sensing G protein coupled receptor (GPCR) that has been identified as a target for possible treatment of type 2 diabetes. A selective activator of GPR120 containing a chromane scaffold has been designed, synthesized, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b516664a4a45395b9f909635d7176636
https://pubmed.ncbi.nlm.nih.gov/28105282
https://pubmed.ncbi.nlm.nih.gov/28105282
Autor:
Wen Feng, Bei Zhang, Songnian Lin, Sunita Malkani, Hsuan-shen Chen, Libo Xu, Jiayi Xu, Rui Zhang, Nadine Elowe, Qinghong Fu, Maria E. Trujillo, Zhesheng Chen, Brian T. Farrer, Robert W. Myers, Michele Pachanski, Michael Kavana, George H. Addona, Daniel R. McMasters, George J. Eiermann, Xinchun Tong, Roman Kats-Kagan, Joel P. Berger, Emma R. Parmee, Brian T. Campbell, Fengqi Zhang, Kaushik Mitra
Publikováno v:
Bioorganicmedicinal chemistry letters. 27(9)
Systemically acting glucokinase activators (GKA) have been demonstrated in clinical trials to effectively lower blood glucose in patients with type II diabetes. However, mechanism-based hypoglycemia is a major adverse effect that limits the therapeut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7740f05d44a9ebea4c672e3b5380708
https://pubmed.ncbi.nlm.nih.gov/28284809
https://pubmed.ncbi.nlm.nih.gov/28284809